ListedMainboardVALIANTLAB
Valiant Laboratories Limited
Valiant Laboratories Limited is a mainboard IPO raising ₹152 Cr at ₹133 – ₹140 a share. It listed on 6 Oct 2023 and trades at ₹61 today, −56.4% against its issue price of ₹140. It was subscribed 30× in total.
₹140
Issue price
₹61
Price now
−56.4%
Since issue price
6 Oct 2023
Listed on
30×Subscribed (final) · all exchanges
29.8 times more demand than shares on offer
populated partly populated we hold nothing here — the tab says why
Who bid for it
| Investor category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| QIB Banks, funds and other large institutions | 21,78,030 | 4,53,61,155 | 21× |
| Foreign Institutional Investors | no separate quota | 1,71,56,055 | n/a |
| Domestic Financial Institutions | no separate quota | 3,62,880 | n/a |
| Mutual funds | no separate quota | 0 | n/a |
| Others | no separate quota | 2,78,42,220 | n/a |
| Non-institutional Wealthy individuals and companies bidding above ₹2 lakh | 16,33,500 | 12,02,87,475 | 74× |
| Non Institutional Investors | 10,88,999 | 8,56,36,635 | 79× |
| Corporates | no separate quota | 6,45,960 | n/a |
| Individuals | no separate quota | 7,37,27,640 | n/a |
| Others | no separate quota | 1,12,63,035 | n/a |
| Non Institutional Investors | 5,44,501 | 3,46,50,840 | 64× |
| Corporates | no separate quota | 54,810 | n/a |
| Individuals | no separate quota | 3,02,83,365 | n/a |
| Others | no separate quota | 43,12,665 | n/a |
| Retail Ordinary investors bidding up to ₹2 lakh | 38,11,500 | 6,11,98,200 | 16× |
| Cut Off | no separate quota | 5,20,57,005 | n/a |
| Price bids | no separate quota | 91,41,195 | n/a |
| Total | 76,23,030 | 22,68,46,830 | 30× |
Sub-categories read no separate quota rather than a dash: the exchange publishes bids at that level but never a reservation against them, so a subscription multiple does not exist — it is not missing data. Bids across both exchanges (NSE and BSE) — the figure usually quoted publicly. Last updated 25 Jul, 07:09 pm IST.
How demand built
We hold no subscription readings for this issue.